Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

10.11EUR
7 Dec 2016
Change (% chg)

€0.04 (+0.35%)
Prev Close
€10.08
Open
€10.10
Day's High
€10.16
Day's Low
€10.02
Volume
160,942
Avg. Vol
214,896
52-wk High
€16.20
52-wk Low
€8.21

Latest Key Developments (Source: Significant Developments)

Ablynx to receive EUR 8 mln milestone as Boehringer Ingelheim starts Phase I study
Thursday, 21 Apr 2016 01:00am EDT 

Ablynx NV:Ablynx to receive an 8 million euros milestone as Boehringer Ingelheim starts a Phase I study with an anti-CX3CR1 nanobody.  Full Article

Ablynx announces warrant exercise
Tuesday, 23 Feb 2016 01:00am EST 

Ablynx NV:Announces warrant exercise.‍Announced that an additional 7,521 common shares have been issued by company in exchange for 34,726.41 euros ($38,324.07) as result of exercise of warrants.‍As a result of this transaction, Ablynx now has 55,108,065 shares outstanding.  Full Article

Ablynx completes enrolment of phase I/IIa safety study with anti-RSV nanobody
Thursday, 17 Dec 2015 01:14am EST 

Ablynx NV:Ablynx completes enrolment of the first-in-infant phase I/IIa safety study with its anti-RSV nanobody and extends the trial for younger infants.Target enrolment of 35 infants, aged 3-24 months, completed.‍On track to publish top line results in first half of 2016​.‍Age requirement for infants in trial has been reduced from 3 months to 1 month.Results from this extension will be available in the second half of 2016.  Full Article

Ablynx says JP Morgan Asset Management Holdings exceeds 3 pct threshold
Wednesday, 2 Dec 2015 01:00am EST 

Ablynx NV:JP Morgan Asset Management Holdings announce 3.33 pct shareholding in Ablynx.JP Morgan Asset Management Holdings notified that they have exceeded the 3 pct threshold and now hold 1,813,725 Ablynx shares.  Full Article

Ablynx announces nanobody drug discovery collaboration with Novo Nordisk
Wednesday, 25 Nov 2015 01:00am EST 

Ablynx NV:Announces nanobody drug discovery collaboration with Novo Nordisk A/S.Ablynx to receive a 5 million euro upfront payment, research funding, potential future milestones and royalties on net sale.If Novo Nordisk decides to exercise option to second programme, company will pay ablynx an exercise fee of 4 million euros.Collaboration and licensing agreement with Novo Nordisk to discover and develop novel multi-specific Nanobody drug candidates.In addition, Ablynx is eligible to receive potential development, regulatory and commercial milestone payments of up to 182 million euros per programme.Novo Nordisk will be responsible for the development, manufacturing and commercialisation of any products resulting from this agreement.  Full Article

Ablynx gives FY 2015 cash burn guidance
Wednesday, 18 Nov 2015 01:00am EST 

Ablynx NV:Company expects its net cash burn for the full year 2015 to be at the lower end of the previously guided range of 70-80 million euros.  Full Article

Ablynx partner Boehringer Ingelheim presented positive in vivo proof-of-mechanism data with bi-specific nanobody
Thursday, 5 Nov 2015 01:00am EST 

Ablynx NV:Ablynx's partner Boehringer Ingelheim presented positive in vivo proof-of-mechanism data with bi-specific nanobody at euro global summit on cancer therapy.  Full Article

Ablynx initiates a multinational phase III study with Caplacizumab in patients with acquired TTP
Tuesday, 29 Sep 2015 01:00am EDT 

Ablynx NV:Initiates a multinational phase III study with Caplacizumab in patients with acquired TTP, a rare blood clotting disorder.Is on track to file for conditional approval of Caplacizumab in Europe in 2017 for treatment of acquired TTP.  Full Article

Ablynx initiates phase II SLE study with its anti-IL-6R Nanobody
Tuesday, 4 Aug 2015 01:00am EDT 

Ablynx NV:Ablynx initiates phase II SLE study with its anti-IL-6R Nanobody, partnered with Abbvie Inc .Study's primary endpoint is the percentage of subjects who achieved a response at week 24 according to the composite BICLA score (BILAG-based Combined Lupus Assessment).  Full Article

Ablynx expands its immuno-oncology collaboration with Merck & Co
Wednesday, 22 Jul 2015 01:00am EDT 

Ablynx NV:Significantly expands its immuno-oncology collaboration with Merck & Co Inc.Expanded deal includes new targets and target combinations directed against immune checkpoint modulators.Expanding size and scope of deal to include up to 12 additional Nanobody programmes.Under terms of this four year expansion, Ablynx will receive a 13 million euro upfront payment.Ablynx will be eligible to receive additional exclusivity fees, depending on the number of programmes for which Merck decides to exercise its licensing option, plus development, regulatory and commercial milestone payments of up to 340 million euros per programme.Also eligible to tiered royalties on annual net sales upon commercialisation of any Nanobody products.  Full Article

BRIEF-Ablynx 9-month net profit turns to 10.9 million euros

* 9-month revenue 68.9 million euros ($73.22 million) versus 53.6 million euros year ago